Clinical Evaluation of Localized Scalp Thread Embedding for Male Androgenetic Alopecia
Launched by BEIJING UNIVERSITY OF CHINESE MEDICINE, SHENZHEN HOSPITAL · Mar 11, 2025
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male sex
- • Age 18-50 years
- • No clinically significant comorbidities
- • Androgenetic alopecia (Hamilton-Norwood III-V)
- • No systemic anti-hair loss therapy use within 3 months
- • No topical hair regrowth agent use within 3 months
- Exclusion Criteria:
- • Active scalp infection
- • Scalp psoriasis
- • Scalp eczema
- • Open scalp wounds
- • Allergy to thread materials
- • Uncontrolled diabetes mellitus
- • Immunodeficiency disorders
- • Non-compliance with follow-up visits
- • Refusal to provide informed consent
- • Investigator-deemed contraindications
About Beijing University Of Chinese Medicine, Shenzhen Hospital
Beijing University of Chinese Medicine, Shenzhen Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital integrates traditional Chinese medicine with modern medical practices to explore novel therapeutic approaches. With a commitment to improving patient outcomes and contributing to global medical knowledge, the institution collaborates with multidisciplinary teams to conduct rigorous studies aimed at enhancing the understanding and treatment of various health conditions. Its state-of-the-art facilities and emphasis on patient-centered care position it as a vital contributor to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported